ID: ALA90896

Max Phase: Preclinical

Molecular Formula: C40H63N7O10

Molecular Weight: 801.98

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COC(=O)CC(O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)CC(O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)OC(C)(C)C

Standard InChI:  InChI=1S/C40H63N7O10/c1-23(2)15-28(32(48)19-34(50)43-25(5)36(52)44-29(16-24(3)4)33(49)20-35(51)56-9)45-38(54)31(18-27-21-41-22-42-27)46-37(53)30(17-26-13-11-10-12-14-26)47-39(55)57-40(6,7)8/h10-14,21-25,28-33,48-49H,15-20H2,1-9H3,(H,41,42)(H,43,50)(H,44,52)(H,45,54)(H,46,53)(H,47,55)/t25-,28-,29-,30-,31-,32?,33?/m0/s1

Standard InChI Key:  NYPYYCAJJQRRHV-BTDLAOMPSA-N

Associated Targets(Human)

Renin 5251 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Renin 163 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Pepsin A 436 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 801.98Molecular Weight (Monoisotopic): 801.4636AlogP: 1.81#Rotatable Bonds: 22
Polar Surface Area: 250.17Molecular Species: NEUTRALHBA: 11HBD: 8
#RO5 Violations: 3HBA (Lipinski): 17HBD (Lipinski): 8#RO5 Violations (Lipinski): 3
CX Acidic pKa: 12.06CX Basic pKa: 6.53CX LogP: 1.55CX LogD: 1.50
Aromatic Rings: 2Heavy Atoms: 57QED Weighted: 0.08Np Likeness Score: 0.09

References

1. Guégan R, Diaz J, Cazaubon C, Beaumont M, Carlet C, Clément J, Demarne H, Mellet M, Richaud JP, Segondy D..  (1986)  Pepstatin analogues as novel renin inhibitors.,  29  (7): [PMID:3543358] [10.1021/jm00157a006]
2. Nisato D, Wagnon J, Callet G, Mettefeu D, Assens JL, Plouzane C, Tonnerre B, Pliska V, Fauchère JL..  (1987)  Renin inhibitors. Free-Wilson and correlation analysis of the inhibitory potency of a series of pepstatin analogues on plasma renin.,  30  (12): [PMID:3316655] [10.1021/jm00395a018]
3. Rich DH..  (1985)  Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analogue inhibitor.,  28  (3): [PMID:3882966] [10.1021/jm00381a001]
4. Maibaum J, Rich DH..  (1988)  Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.,  31  (3): [PMID:3126296] [10.1021/jm00398a022]
5. Maibaum J, Rich DH..  (1988)  Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases.,  31  (3): [PMID:3126296] [10.1021/jm00398a022]

Source